Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy

用于人类干细胞治疗的新型 NSG 小鼠模型的开发和验证

基本信息

项目摘要

DESCRIPTION (provided by applicant): Stem cell therapy is rapidly advancing into the clinic, but there remains a critical need for effective experimental models for in vivo analyses of human stem cells to evaluate their efficacy and safety. Although rodent models have provided fundamental insights into disease mechanisms, mice and humans differ in terms of cell composition, function, and gene expression. We propose to address this species-specific issue using novel humanized mouse models that meet urgent needs of multiple institutes at NIH. Our novel models of humanized mice based on our creation of NOD-scid IL2rgnull (NSG) and NOD-Raglnull IL2rgnull (NRG) strains will support the in vivo study of human stem cell biology and permit evaluation of the efficacy of human stem cells for the treatment of diseases. Our preliminary data describes development of novel humanized mouse models that support engraftment with functional human hematopoietic, lymphoid, and hepatic stem cells and that we are developing models for the study of human neuronal stem cells for the treatment of amyotrophic lateral sclerosis and muscle stem cells for the treatment of muscular dystrophy. In all of these models, the mechanisms underlying the ability of human mesenchymal stem cells to enhance engraftment of tissue-specific human stem cell populations and increase their therapeutic efficacy can be investigated. In this multi-PI, multi-disciplinary team proposal, we propose three Aims that will: 1) Generate new models of immunodeficient mice for the functional in vivo evaluation of human stem cells; 2) Validate the models by determining the ability of human stem cells to generate functional differentiated human cells and tissues in vivo that ameliorate disease, and; 3) Leverage the world-wide distribution resources of The Jackson Laboratory to make these new humanized mouse models rapidly available to the scientific community. Our proposal takes advantage of powerful new technologies for creating new models of humanized mice, and builds on our >20 year track record for generating, validating, and sharing of novel models of humanized mice. These models developed and validated by our multi-disciplinary team will be rapidly distributed to the scientific community, uniquely positionig us to achieve the goals of this RFA.
描述(申请人提供):干细胞疗法正在迅速进入临床,但仍然迫切需要有效的实验模型来对人体干细胞进行体内分析,以评估其有效性和安全性。尽管啮齿动物模型提供了对疾病机制的基本见解,但小鼠和人类在细胞组成、功能和基因表达方面存在差异。我们建议使用新的人源化小鼠模型来解决这个特定物种的问题,这些模型可以满足NIH多个研究所的迫切需求。基于我们创建的NOD-SCID IL2rgnull(NSG)和NOD-RaglullIL2rgnull(NRG)菌株,我们的新型人源化小鼠模型将支持人类干细胞生物学的体内研究,并允许评估人类干细胞治疗疾病的有效性。我们的初步数据描述了新型人源化小鼠模型的开发,这些模型支持植入具有功能的人造血干细胞、淋巴样干细胞和肝脏干细胞,我们正在开发用于治疗肌萎缩侧索硬化症的人类神经干细胞和用于治疗肌营养不良的肌肉干细胞的研究模型。在所有这些模型中,可以研究人类间充质干细胞促进组织特异性人类干细胞群体植入和提高其治疗效果的潜在机制。在这个多PI、多学科的团队提案中,我们提出了三个目标:1)建立新的免疫缺陷小鼠模型,用于体内人类干细胞的功能评估;2)通过确定人类干细胞在体内产生功能性分化的人类细胞和组织以改善疾病的能力来验证模型;以及3)利用杰克逊实验室在世界各地的分布资源,使这些新的人源化小鼠模型迅速提供给科学界。我们的建议利用强大的新技术来创建新的人性化小鼠模型,并建立在我们在生成、验证和共享新型人性化小鼠模型方面20年的跟踪记录的基础上。这些由我们的多学科团队开发和验证的模型将迅速分发给科学界,为我们实现RFA的目标提供独特的地位。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Allen Brehm其他文献

Michael Allen Brehm的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Allen Brehm', 18)}}的其他基金

Immunogenicity of Human Stem Cell-Derived Beta Cells and Muscle Cells in Humanized Mice
人类干细胞衍生的β细胞和肌肉细胞在人源化小鼠中的免疫原性
  • 批准号:
    10218287
  • 财政年份:
    2019
  • 资助金额:
    $ 78.04万
  • 项目类别:
Immunogenicity of Human Stem Cell-Derived Beta Cells and Muscle Cells in Humanized Mice
人类干细胞衍生的β细胞和肌肉细胞在人源化小鼠中的免疫原性
  • 批准号:
    10449121
  • 财政年份:
    2019
  • 资助金额:
    $ 78.04万
  • 项目类别:
Humanized mice for investigating human stem cell-derived microglia in Alzheimers Disease
用于研究阿尔茨海默病中人类干细胞衍生的小胶质细胞的人源化小鼠
  • 批准号:
    10120199
  • 财政年份:
    2019
  • 资助金额:
    $ 78.04万
  • 项目类别:
Live imaging of SARS-CoV-2 infection in novel humanized mice
新型人源化小鼠中 SARS-CoV-2 感染的实时成像
  • 批准号:
    10400392
  • 财政年份:
    2019
  • 资助金额:
    $ 78.04万
  • 项目类别:
Novel humanized mouse model developed from cord blood CD34 positive HSC and autologous iPS cell derived thymus
由脐带血CD34阳性HSC和自体iPS细胞衍生胸腺开发的新型人源化小鼠模型
  • 批准号:
    9915858
  • 财政年份:
    2017
  • 资助金额:
    $ 78.04万
  • 项目类别:
Novel humanized mouse model developed from cord blood CD34 positive HSC and autologous iPS cell derived thymus
由脐带血CD34阳性HSC和自体iPS细胞衍生胸腺开发的新型人源化小鼠模型
  • 批准号:
    9368151
  • 财政年份:
    2017
  • 资助金额:
    $ 78.04万
  • 项目类别:
Novel humanized mouse model developed from cord blood CD34 positive HSC and autologous iPS cell derived thymus
由脐带血CD34阳性HSC和自体iPS细胞衍生胸腺开发的新型人源化小鼠模型
  • 批准号:
    10153677
  • 财政年份:
    2017
  • 资助金额:
    $ 78.04万
  • 项目类别:
Humanized Mouse Avatars for T1D
T1D 人性化鼠标头像
  • 批准号:
    10170353
  • 财政年份:
    2014
  • 资助金额:
    $ 78.04万
  • 项目类别:
Retrogenic humanized mice for the study of T1D
用于 T1D 研究的逆基因人源化小鼠
  • 批准号:
    8728475
  • 财政年份:
    2014
  • 资助金额:
    $ 78.04万
  • 项目类别:
Humanized Mouse Avatars for T1D
T1D 人性化鼠标头像
  • 批准号:
    10020970
  • 财政年份:
    2014
  • 资助金额:
    $ 78.04万
  • 项目类别:

相似海外基金

Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.04万
  • 项目类别:
    Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
  • 批准号:
    MR/Y014286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.04万
  • 项目类别:
    Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
  • 批准号:
    MR/Y503502/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.04万
  • 项目类别:
    Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
    Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
  • 批准号:
    10759808
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
  • 批准号:
    10606865
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
  • 批准号:
    10848139
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
  • 批准号:
    MR/Y001095/1
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
    Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
  • 批准号:
    488892
  • 财政年份:
    2023
  • 资助金额:
    $ 78.04万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了